WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H561441
CAS#: 148869-05-0
Description: YM511 is a non-steroidal selective aromatase inhibitor. YM511 may be useful in the treatment of estrogen-dependent cancers without affecting serum levels of other steroid hormones.
Hodoodo Cat#: H561441
Name: YM511
CAS#: 148869-05-0
Chemical Formula: C16H12BrN5
Exact Mass: 353.03
Molecular Weight: 354.210
Elemental Analysis: C, 54.25; H, 3.41; Br, 22.56; N, 19.77
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: YM511; YM-511; YM 511;
IUPAC/Chemical Name: 4-[(4-Bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile
InChi Key: GGPPBTSXFROGAE-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12BrN5/c17-15-5-1-14(2-6-15)10-22(21-11-19-20-12-21)16-7-3-13(9-18)4-8-16/h1-8,11-12H,10H2
SMILES Code: N#CC1=CC=C(N(CC2=CC=C(Br)C=C2)N3C=NN=C3)C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 354.21 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Song J, Wu Z, Wangtrakuldee B, Choi SR, Zha Z, Ploessl K, Mach RH, Kung H. 4-(((4-Iodophenyl)methyl)-4H-1,2,4-triazol-4-ylamino)-benzonitrile: A Potential Imaging Agent for Aromatase. J Med Chem. 2016 Oct 27;59(20):9370-9380. Epub 2016 Oct 11. PubMed PMID: 27690428.
2: Takahashi K, Hosoya T, Onoe K, Doi H, Nagata H, Hiramatsu T, Li XL, Watanabe Y, Wada Y, Takashima T, Suzuki M, Onoe H, Watanabe Y. 11C-cetrozole: an improved C-11C-methylated PET probe for aromatase imaging in the brain. J Nucl Med. 2014 May;55(5):852-7. doi: 10.2967/jnumed.113.131474. Epub 2014 Mar 27. PubMed PMID: 24676756.
3: Woo LW, Bubert C, Sutcliffe OB, Smith A, Chander SK, Mahon MF, Purohit A, Reed MJ, Potter BV. Dual aromatase-steroid sulfatase inhibitors. J Med Chem. 2007 Jul 26;50(15):3540-60. Epub 2007 Jun 20. PubMed PMID: 17580845.
4: Wood PM, Woo LW, Humphreys A, Chander SK, Purohit A, Reed MJ, Potter BV. A letrozole-based dual aromatase-sulphatase inhibitor with in vivo activity. J Steroid Biochem Mol Biol. 2005 Feb;94(1-3):123-30. Epub 2005 Feb 5. PubMed PMID: 15862957.
5: Dowsett M, Haynes BP. Hormonal effects of aromatase inhibitors: focus on premenopausal effects and interaction with tamoxifen. J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):255-63. Review. PubMed PMID: 14623519.
6: Tominaga T, Suzuki T. Early phase II study of the new aromatase inhibitor YM511 in postmenopausal patients with breast cancer. Difficulty in clinical dose recommendation based on preclinical and phase I findings. Anticancer Res. 2003 Jul-Aug;23(4):3533-42. PubMed PMID: 12926103.
7: Woo LW, Sutcliffe OB, Bubert C, Grasso A, Chander SK, Purohit A, Reed MJ, Potter BV. First dual aromatase-steroid sulfatase inhibitors. J Med Chem. 2003 Jul 17;46(15):3193-6. PubMed PMID: 12852749.
8: Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H. Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial explants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol. 1997 Sep-Oct;63(1-3):75-80. PubMed PMID: 9449208.
9: Okada M, Yoden T, Kawaminami E, Shimada Y, Kudoh M, Isomura Y. Studies on aromatase inhibitors. IV. Synthesis and biological evaluation of N,N-disubstituted-5-aminopyrimidine derivatives. Chem Pharm Bull (Tokyo). 1997 Aug;45(8):1293-9. PubMed PMID: 9301028.
10: Okada M, Yoden T, Kawaminami E, Shimada Y, Kudoh M, Isomura Y. Studies on aromatase inhibitors. III. Synthesis and biological evaluation of [(4-bromobenzyl)(4-cyanophenyl)amino]azoles and their azine analogs. Chem Pharm Bull (Tokyo). 1997 Mar;45(3):482-6. PubMed PMID: 9085555.
11: Okada M, Yoden T, Kawaminami E, Shimada Y, Kudoh M, Isomura Y, Shikama H, Fujikura T. Studies on aromatase inhibitors. I. Synthesis and biological evaluation of 4-amino-4H-1,2,4-triazole derivatives. Chem Pharm Bull (Tokyo). 1996 Oct;44(10):1871-9. PubMed PMID: 8904814.
12: Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M, Shikama H, Fujikura T. Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. J Steroid Biochem Mol Biol. 1996 May;58(2):189-94. PubMed PMID: 8809200.
13: Kudoh M, Susaki Y, Ideyama Y, Nanya T, Okada M, Shikama H, Fujikura T. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol. 1995 Sep;54(5-6):265-71. PubMed PMID: 7577709.
